Long-term results from the phase III TRIANGLE trial show ibrutinib-based regimens improve survival in younger mantle cell lymphoma patients, while the ECHO trial establishes a new standard for older patients. Advances in CAR T-cell and bispecific antibody therapies are reshaping treatment for this rare blood cancer. The findings were presented at the annual MCL Consortium meeting.
A phase II trial of TAK-007 CAR-NK therapy in R/R B-cell NHL showed a 60.9% overall response rate. Preclinical CAR-NKT therapy eliminated endometrial tumors in models. Optimized costimulatory domains (2B4-DAP12) boosted CAR-NK tumor killing.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07713511 |
INfections in Patients Treated With CAR-T |
NOT_YET_RECRUITING | |
| NCT07661537 |
A Clinical Study of SHR-3079 in B-cell Non-Hodgkin Lymphoma |
RECRUITING | PHASE1 |
| NCT07658352 |
A First-in-Human Study of HP-002 for Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma |
NOT_YET_RECRUITING | PHASE1/PHASE2 |
| NCT07220616 |
A First-in-Human Trial of DS3790a in Participants With Hematological Malignancies |
RECRUITING | PHASE1/PHASE2 |
| NCT07123454 |
A Phase I/II Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma |
RECRUITING | PHASE1/PHASE2 |
| NCT06564038 |
A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies |
RECRUITING | PHASE1/PHASE2 |
| NCT06526793 |
Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL |
RECRUITING | PHASE2 |
| NCT06464185 |
A Prospective Clinical Study of CD3-CD20 Bisspecific Antibody Based Therapy Combined With CD19-CAR T Cells in the Treatment of Relapsed Refractory B-cell Non-Hodgkin Lymphoma |
ACTIVE_NOT_RECRUITING | PHASE1/PHASE2 |
| NCT06242834 |
Pembrolizumab and Tazemetostat to Overcome Immune Tolerance Following ASCT or CAR T-cell Therapy in Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma |
ACTIVE_NOT_RECRUITING | PHASE2 |
| NCT05365659 |
IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas |
RECRUITING | PHASE1 |
